Skip to main content

10-08-2018 | Non-small-cell lung cancer | News | Article

News in brief

AURA3: Osimertinib shows superior CNS efficacy in advanced NSCLC

medwireNews: The superior systemic effects of the epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor (TKI) osimertinib over chemotherapy extend to central nervous system (CNS) metastases in previously treated patients with advanced non-small-cell lung cancer (NSCLC), say the AURA3 investigators.

As described in the Journal of Clinical Oncology, 46 of the trial participants – all of whom had progressed after prior EGFR–TKI treatment and harbored the EGFR T790M mutation – had measurable but asymptomatic CNS metastases at baseline.

Of the 30 patients who received the third-generation EGFR–TKI as per the random assignment, 70% achieved an objective CNS response, as did 31% of the 16 patients given pemetrexed plus cisplatin or carboplatin, a significant difference.

The CNS progression-free survival was likewise significantly improved with osimertinib 80 mg/day than chemotherapy, with respective medians of 11.7 and 5.6 months.

“The consistent efficacy across CNS analyses in the phase II and phase III studies indicates that osimertinib offers robust and durable efficacy against CNS metastases in patients with T790M-positive NSCLC and disease progression with first-line EGFR-TKI, an area of high unmet medical need,” conclude Yi-Long Wu (Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China) and co-researchers.

By Shreeya Nanda

medwireNews is an independent medical news service provided by Springer Healthcare. © 2018 Springer Healthcare part of the Springer Nature group

See also:

Related topics

See the research in context now

with trial summaries, expert opinion and congress coverage